TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) earnings date
Jan 27, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 30 days, typically, give or take 4 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | before open | 34 | 8-K |
| Q2 FY2026 | Wed, Jul 29, 2026 | before open | 29 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | before open | 29 | 8-K |
| Q4 FY2025 | Wed, Jan 28, 2026 | before open | 28 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Wed, Jul 30, 2025 | before open | 30 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 37 | 8-K |
| Q4 FY2024 | Wed, Jan 29, 2025 | before open | 29 | 8-K |
What they guided beta
| Q3 FY2026 | "EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion" exhibit |
| Q3 FY2026 | "Q3 2026 revenues of $4.4 billion , a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules (a generic version of Revlimid ® ) in the U.S. This decrease was partially offset by continued strong growth across Teva’s key innovative brands." exhibit |
| Q3 FY2026 | "Teva is raising its 2026 revenue outlook to $2.55 billion–$2.65 billion, from $2.45 billion–$2.60 billion." exhibit Read from the sentence: revenue $2.55 billion to $2.65 billion, FY2026 |
| Q3 FY2026 | "Teva is raising its 2026 revenue outlook to $930 million–$960 million, from $850 million–$870 million." exhibit Read from the sentence: revenue $930 million to $960 million, FY2026 |
| Q3 FY2026 | "Teva
is raising its 2026 revenue outlook to $290 million–$310 million, from $270 million–$290 million." exhibit Read from the sentence: revenue $290 million to $310 million, FY2026 |
| Q2 FY2026 | "EXHIBIT 99.1 Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy" exhibit |
| Q2 FY2026 | "Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues." exhibit |
| Q2 FY2026 | "Our key innovative brands collectively grew 43% YoY in LC, to over $1 billion in revenues, and we raised our 2026 outlook for all three, highlighting Teva’s continued execution of its Pivot to Growth strategy." exhibit |
| Q2 FY2026 | "UZEDY continues to be the fastest growing LAI amongst atypical LAI’s for schizophrenia, creating a strong foundation for Teva's schizophrenia franchise. 1 Teva is raising its 2026 revenue outlook for each of these key innovative brands, and now expects combined 2026 revenue of ~$3.7 billion reflecting a ~17% YoY growth at the mid-point." exhibit |
| Q2 FY2026 | "Generics Powerhouse: generics global revenues were lower in Q2 2026 vs." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TEVA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TEVA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TEVA/"><img src="https://veritasdata.dev/embed/TEVA.svg" alt="TEVA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TEVA/)
Script
<script async src="https://veritasdata.dev/embed/TEVA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TEVA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.